Cargando…
Resistance to Integrase Inhibitors
Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN codin...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920056/ https://www.ncbi.nlm.nih.gov/pubmed/20706558 http://dx.doi.org/10.3390/v2071347 |